Convalescent Plasma in COVID-19 Patients. Hope Fades
Keywords:
COVID-19, Coronavirus, Convalescent plasma, SARS-CoV-2, passive immunotherapyAbstract
For more than a century, convalescent plasma has been used as a passive immunization strategy to treat infectious diseases. It has been widely used to treat coronavirus disease under the assumption that such plasma contains potentially therapeutic antibodies against SARS-CoV-2. The objective of this article is to evaluate the clinical efficacy of convalescent plasma for the treatment of COVID-19. Evidence on its use in COVID-19 patients in recent weeks has been supported by more robust and consistent studies. Therefore, we consider that there is insufficient certainty and quality of evidence to recommend the use of convalescent plasma to prevent or treat outpatients or hospitalized patients with COVID-19. More research and solid arguments are needed before regulatory bodies recommend and include it in their protocols.
Downloads
References
Subbarao K, Mordant F, Rudraraju R. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience. Eur J Immunol 2020[Acceso 23/02/2021];50:1447-53. Disponible en: https://doi.org/10.1002/eji.202048723
Serrano-Barrera OR, Bello-Rodríguez MM. Plasma humano de convalecientes, ahora un tratamiento para la COVID-19, tuvo su origen en Cuba. Rev. electrón. Zoilo. 2020 [Acceso 09/03/2021];45(4):[aprox. 3 p.]. Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/2277
Beigel JH, Aga E, Elie-Turenne MC, Cho J, Tebas P, Clark C.L, Stapleton RD. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019[Acceso 20/03/2021];7(11):941-950. Disponible en:doi: 10.1016/S2213-2600(19)30199-7 PMCID: PMC6941345
Infectious Diseases Society of America. Clarifying the Emergency Use Authorization framework for COVID- convalescent plasma: considerations for clinicians prepared jointly by the Infectious Diseases Society of America and AABB. [Acceso 20/03/2021];November. Disponible en: https://www.idsociety.org/globalassets/covid--real-timelearning-network/therapeutics-and-interventions/convalescent-plasma/aabb-idsa-convalescent-plasma-eua--nal.pdf
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic Proceedings. 2020 [Acceso 20/02/2021] ;95(9):1888-97. Disponible en: https://doi.org/10.1016/J.MAYOCP.2020.06.028
US Food and Drug Administration. FDA issues Emergency Use Authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration’s fight against pandemic. [Acceso 15/02/2021];Published August/ 23/2020. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582-9. doi:10.1001/jama.2020.4783 PMCID: PMC7101507
Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890-901. doi: 10.1002/jmv.25882 PMCID: PMC7262027
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-6. doi: 10.1073/pnas.2004168117 PMCID: PMC7196837
Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: A pilot study. Rev Invest Clin. 2020;72(3):159-64. doi: 10.24875/RIC.20000237 PMID: 32584322
Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci. 2020;59(5):102867. doi: 10.1016/j.transci.2020.102867 PMID: 32620409
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MHL, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6. doi: 10.1007/s10096-004-1271-9 PMCID: PMC7088355
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Liu Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020. 4;324(5):460-70. doi: 10.1001/jama.2020.10044 PMID: 32492084
Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021;325(12):1185-95. doi:10.1001/jama.2021.2747
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371. doi:10.1136/bmj.m3939 PMCID: PMC7578662
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Belloso WH. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021;384(7):619-629. doi:10.1056/NEJMoa2031304 PMCID: PMC7722692
RECOVERY Trial. Press release: RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalized with COVID-19. Published January 15, 2021. [Acceso 25/03/2021]; Disponible en: https://www.recoverytrial.net/news/statement-from-the-recovery-trial-chief-investigators-15-january-2021-recovery-trial-closes-recruitment-to-convalescent-plasma-treatment-for-patients-hospitalised-with-covid-19
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
